Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon their potential impact for early risk assessment in asymptomatic Chagas' patients

Official URL:https://doi.org/10.1016/j.jacc.2009.06.064
PubMed:View item in PubMed
Creators Name:Wallukat, G. and Munoz Saravia, S.G. and Haberland, A. and Bartel, S. and Araujo, R. and Valda, G. and Duchen, D. and Diaz Ramirez, I. and Borges, A.C. and Schimke, I.
Journal Title:Journal of the American College of Cardiology
Journal Abbreviation:J Am Coll Cardiol
Volume:55
Number:5
Page Range:463-468
Date:2 February 2010
Keywords:Autoantibodies, Cardiomyopathy, Chagas' Disease, Megacolon, Risk Assessment, Animals, Rats
Abstract:OBJECTIVES: Distinguishing the patterns of autoantibodies (AAB) against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon and the discovery of such a pattern in patients who are as yet asymptomatic could help to identify patients at high risk of developing the life-threatening complications of Chagas' disease. BACKGROUND: Such AAB against receptors as beta 1 (beta1-AAB), beta 2 (beta2-AAB), and muscarinergic 2 (M2-AAB) are thought to be involved in the pathogenesis of Chagas' cardiomyopathy and megacolon, the predominant manifestations of Chagas' disease, which is the most serious parasitic disease in Latin America. METHODS: Beta1-AAB, beta2-AAB, and M2-AAB were measured in the serum of asymptomatic Chagas' patients and in those with cardiomyopathy and/or megacolon. RESULTS: Nearly all Chagas' patients with cardiomyopathy and/or megacolon had AAB. Predominance of beta1-AAB combined with M2-AAB in Chagas' cardiomyopathy and beta2-AAB with M2-AAB in megacolon was found. Such patterns were also found in 34% of the asymptomatic patients, of whom 85% possessed a beta1-AAB level typical for Chagas' cardiomyopathy. CONCLUSIONS: The percentage of asymptomatic Chagas' patients who had a specific AAB pattern and had a beta1-AAB level above a defined cutoff point mirrors very well the epidemiological situation, which showed that clinical manifestations develop in nearly 30% of Chagas' patients and cardiomyopathy in nearly 90% of them. We hypothesize that beta1-, beta2-, and M2-AAB measurement might be a useful tool for risk assessment in the indeterminate state of Chagas' disease to select patients for earlier involvement in care programs. However, prospective studies are needed to further evaluate this hypothesis.
ISSN:0735-1097
Publisher:Elsevier (U.S.A.)
Item Type:Article

Repository Staff Only: item control page

Open Access
MDC Library